 Andrea Steck
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 116 | 2025 | 3705 | 8.820 |
Why?
| | Autoantibodies | 75 | 2025 | 1457 | 7.550 |
Why?
| | Islets of Langerhans | 42 | 2025 | 792 | 4.460 |
Why?
| | Autoimmunity | 35 | 2024 | 904 | 2.920 |
Why?
| | C-Peptide | 15 | 2025 | 163 | 2.760 |
Why?
| | Insulin Antibodies | 11 | 2022 | 100 | 2.360 |
Why?
| | Genetic Predisposition to Disease | 34 | 2025 | 2362 | 1.960 |
Why?
| | Polymorphism, Single Nucleotide | 24 | 2025 | 2138 | 1.870 |
Why?
| | Blood Glucose | 15 | 2025 | 2241 | 1.670 |
Why?
| | Glutamate Decarboxylase | 17 | 2022 | 165 | 1.660 |
Why?
| | Disease Progression | 35 | 2024 | 2752 | 1.550 |
Why?
| | Insulin | 22 | 2025 | 2447 | 1.510 |
Why?
| | Hyperglycemia | 3 | 2024 | 357 | 1.360 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 7 | 2019 | 44 | 1.350 |
Why?
| | Child | 85 | 2025 | 21936 | 1.350 |
Why?
| | HLA-DR Antigens | 8 | 2016 | 228 | 1.270 |
Why?
| | Child, Preschool | 57 | 2025 | 11158 | 1.260 |
Why?
| | HLA-DQ Antigens | 9 | 2024 | 177 | 1.170 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2025 | 2516 | 1.130 |
Why?
| | HLA-DR3 Antigen | 9 | 2024 | 77 | 1.120 |
Why?
| | Adolescent | 66 | 2025 | 21581 | 1.090 |
Why?
| | Genotype | 22 | 2020 | 1849 | 1.080 |
Why?
| | Diabetic Ketoacidosis | 4 | 2024 | 202 | 0.970 |
Why?
| | Infant | 35 | 2024 | 9577 | 0.920 |
Why?
| | Blood Glucose Self-Monitoring | 7 | 2025 | 684 | 0.900 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2017 | 54 | 0.870 |
Why?
| | Precision Medicine | 2 | 2025 | 421 | 0.830 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2017 | 429 | 0.820 |
Why?
| | Humans | 131 | 2025 | 138972 | 0.820 |
Why?
| | Male | 86 | 2025 | 68250 | 0.820 |
Why?
| | Insulin-Secreting Cells | 11 | 2021 | 374 | 0.800 |
Why?
| | Genetic Testing | 7 | 2025 | 453 | 0.770 |
Why?
| | Female | 86 | 2025 | 74016 | 0.770 |
Why?
| | Haplotypes | 9 | 2024 | 497 | 0.770 |
Why?
| | Mass Screening | 11 | 2025 | 1296 | 0.760 |
Why?
| | Zinc Transporter 8 | 7 | 2021 | 62 | 0.750 |
Why?
| | Young Adult | 37 | 2025 | 13371 | 0.730 |
Why?
| | HLA-D Antigens | 2 | 2019 | 32 | 0.680 |
Why?
| | Age of Onset | 12 | 2021 | 521 | 0.680 |
Why?
| | HLA-DR4 Antigen | 6 | 2024 | 76 | 0.660 |
Why?
| | Prediabetic State | 4 | 2023 | 248 | 0.650 |
Why?
| | Glucose Tolerance Test | 9 | 2025 | 366 | 0.640 |
Why?
| | Diabetes Mellitus | 3 | 2025 | 1068 | 0.620 |
Why?
| | HLA Antigens | 5 | 2022 | 233 | 0.610 |
Why?
| | Prospective Studies | 22 | 2024 | 7661 | 0.610 |
Why?
| | Risk Factors | 31 | 2025 | 10385 | 0.600 |
Why?
| | C-Reactive Protein | 2 | 2018 | 411 | 0.590 |
Why?
| | Family | 5 | 2025 | 680 | 0.570 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2017 | 14 | 0.540 |
Why?
| | Celiac Disease | 4 | 2022 | 291 | 0.510 |
Why?
| | Hypoglycemic Agents | 5 | 2020 | 1343 | 0.500 |
Why?
| | Sensitivity and Specificity | 9 | 2022 | 1939 | 0.490 |
Why?
| | DNA Methylation | 5 | 2024 | 636 | 0.450 |
Why?
| | Case-Control Studies | 12 | 2021 | 3574 | 0.450 |
Why?
| | Models, Genetic | 1 | 2017 | 591 | 0.440 |
Why?
| | Proinsulin | 2 | 2020 | 52 | 0.430 |
Why?
| | Polymorphism, Genetic | 5 | 2019 | 624 | 0.410 |
Why?
| | Follow-Up Studies | 11 | 2021 | 5152 | 0.390 |
Why?
| | Adult | 34 | 2025 | 38393 | 0.390 |
Why?
| | Luminescent Measurements | 4 | 2021 | 74 | 0.390 |
Why?
| | Luminescence | 4 | 2016 | 37 | 0.390 |
Why?
| | HLA-DQ beta-Chains | 4 | 2019 | 62 | 0.390 |
Why?
| | Transcription Factor 7-Like 2 Protein | 5 | 2021 | 26 | 0.380 |
Why?
| | Cation Transport Proteins | 4 | 2017 | 109 | 0.370 |
Why?
| | Twins, Monozygotic | 5 | 2025 | 189 | 0.360 |
Why?
| | Quality Improvement | 2 | 2017 | 1215 | 0.360 |
Why?
| | Risk | 6 | 2019 | 913 | 0.310 |
Why?
| | HLA-DQ alpha-Chains | 3 | 2019 | 16 | 0.300 |
Why?
| | Antigens, CD | 2 | 2009 | 537 | 0.290 |
Why?
| | Family Health | 4 | 2017 | 195 | 0.290 |
Why?
| | Longitudinal Studies | 7 | 2024 | 2850 | 0.290 |
Why?
| | Risk Assessment | 6 | 2025 | 3466 | 0.280 |
Why?
| | Predictive Value of Tests | 7 | 2019 | 2030 | 0.280 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 110 | 0.280 |
Why?
| | Cohort Studies | 11 | 2021 | 5744 | 0.280 |
Why?
| | Transglutaminases | 2 | 2021 | 155 | 0.280 |
Why?
| | Major Histocompatibility Complex | 4 | 2017 | 233 | 0.270 |
Why?
| | Colorado | 6 | 2024 | 4543 | 0.270 |
Why?
| | Pancreas | 3 | 2024 | 322 | 0.260 |
Why?
| | CTLA-4 Antigen | 3 | 2017 | 99 | 0.260 |
Why?
| | Alleles | 4 | 2021 | 890 | 0.250 |
Why?
| | Age Factors | 6 | 2022 | 3276 | 0.240 |
Why?
| | Autoimmune Diseases | 3 | 2017 | 455 | 0.240 |
Why?
| | Autoantigens | 2 | 2021 | 422 | 0.230 |
Why?
| | Diabetes Complications | 2 | 2018 | 224 | 0.230 |
Why?
| | Prognosis | 7 | 2021 | 3995 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2006 | 167 | 0.230 |
Why?
| | Twins, Dizygotic | 3 | 2025 | 162 | 0.220 |
Why?
| | Hydroxychloroquine | 1 | 2023 | 56 | 0.200 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1097 | 0.200 |
Why?
| | Gene Frequency | 6 | 2020 | 501 | 0.200 |
Why?
| | Biomarkers | 6 | 2021 | 4095 | 0.200 |
Why?
| | Neurology | 1 | 2024 | 111 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1281 | 0.200 |
Why?
| | Glucokinase | 2 | 2013 | 15 | 0.190 |
Why?
| | Phenotype | 3 | 2024 | 3143 | 0.190 |
Why?
| | Radioimmunoassay | 3 | 2017 | 169 | 0.180 |
Why?
| | Infant, Newborn | 7 | 2022 | 6158 | 0.180 |
Why?
| | Prevalence | 3 | 2024 | 2745 | 0.180 |
Why?
| | Chromosome Mapping | 2 | 2021 | 505 | 0.180 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1391 | 0.170 |
Why?
| | Early Diagnosis | 3 | 2020 | 240 | 0.170 |
Why?
| | Seroconversion | 1 | 2021 | 46 | 0.170 |
Why?
| | Area Under Curve | 2 | 2020 | 319 | 0.170 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 152 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 835 | 0.160 |
Why?
| | Iodide Peroxidase | 2 | 2020 | 26 | 0.160 |
Why?
| | Middle Aged | 14 | 2025 | 33782 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 219 | 0.150 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1985 | 0.150 |
Why?
| | Down-Regulation | 1 | 2021 | 636 | 0.140 |
Why?
| | Incidence | 4 | 2022 | 2830 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2022 | 718 | 0.140 |
Why?
| | Insulin Resistance | 3 | 2021 | 1222 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 897 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1497 | 0.140 |
Why?
| | Genetic Association Studies | 4 | 2025 | 373 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 699 | 0.140 |
Why?
| | Receptors, CCR7 | 1 | 2017 | 32 | 0.140 |
Why?
| | Discriminant Analysis | 1 | 2017 | 37 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 564 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 59 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2021 | 787 | 0.130 |
Why?
| | Fasting | 2 | 2018 | 283 | 0.130 |
Why?
| | Blood Specimen Collection | 1 | 2017 | 37 | 0.130 |
Why?
| | Immunoglobulin M | 2 | 2021 | 287 | 0.130 |
Why?
| | Consensus | 3 | 2024 | 683 | 0.130 |
Why?
| | Health Care Costs | 1 | 2020 | 419 | 0.130 |
Why?
| | Transcription Factors | 2 | 2017 | 1701 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 621 | 0.130 |
Why?
| | Influenza, Human | 1 | 2022 | 614 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 990 | 0.120 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 797 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 704 | 0.120 |
Why?
| | Hypoglycemia | 2 | 2020 | 460 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1244 | 0.120 |
Why?
| | Iron-Binding Proteins | 1 | 2015 | 43 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 100 | 0.110 |
Why?
| | Peptides | 1 | 2021 | 980 | 0.110 |
Why?
| | RNA, Long Noncoding | 1 | 2017 | 171 | 0.110 |
Why?
| | Trans-Activators | 1 | 2017 | 391 | 0.110 |
Why?
| | Dried Blood Spot Testing | 1 | 2015 | 121 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 464 | 0.110 |
Why?
| | Self Care | 1 | 2017 | 387 | 0.110 |
Why?
| | Repressor Proteins | 1 | 2017 | 423 | 0.110 |
Why?
| | Europe | 3 | 2024 | 407 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2013 | 14 | 0.100 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2013 | 7 | 0.100 |
Why?
| | Glucose | 3 | 2023 | 1031 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1437 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 20 | 0.100 |
Why?
| | Population Surveillance | 1 | 2017 | 482 | 0.100 |
Why?
| | Genetic Linkage | 2 | 2011 | 289 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 96 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3636 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 85 | 0.100 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 910 | 0.090 |
Why?
| | United Kingdom | 3 | 2018 | 321 | 0.090 |
Why?
| | Stroke | 2 | 2010 | 1140 | 0.090 |
Why?
| | Proteins | 1 | 2017 | 1009 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1047 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1235 | 0.090 |
Why?
| | Penetrance | 1 | 2011 | 28 | 0.090 |
Why?
| | Siblings | 2 | 2018 | 216 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2047 | 0.080 |
Why?
| | Atrial Natriuretic Factor | 1 | 2010 | 54 | 0.080 |
Why?
| | Skin | 1 | 2015 | 756 | 0.080 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 165 | 0.080 |
Why?
| | Gene Expression | 2 | 2021 | 1487 | 0.080 |
Why?
| | Glycopeptides | 1 | 2010 | 43 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1473 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 399 | 0.080 |
Why?
| | Inflammation | 2 | 2020 | 2853 | 0.080 |
Why?
| | Genetic Markers | 1 | 2011 | 344 | 0.080 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 205 | 0.080 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2011 | 366 | 0.080 |
Why?
| | TCF Transcription Factors | 1 | 2008 | 17 | 0.070 |
Why?
| | Obesity | 2 | 2019 | 2994 | 0.070 |
Why?
| | Nuclear Family | 1 | 2009 | 57 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 761 | 0.070 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 90 | 0.070 |
Why?
| | Metabolomics | 2 | 2025 | 689 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 74 | 0.070 |
Why?
| | Mutation | 2 | 2015 | 3984 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 43 | 0.060 |
Why?
| | Gene-Environment Interaction | 2 | 2020 | 186 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2228 | 0.060 |
Why?
| | CpG Islands | 2 | 2016 | 159 | 0.060 |
Why?
| | Biosensing Techniques | 1 | 2007 | 133 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2024 | 644 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 571 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3313 | 0.060 |
Why?
| | Cell Death | 2 | 2019 | 375 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 82 | 0.060 |
Why?
| | Environment | 2 | 2018 | 340 | 0.060 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.060 |
Why?
| | Interleukin-4 | 1 | 2005 | 214 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2010 | 766 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 148 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2021 | 748 | 0.050 |
Why?
| | Animals | 4 | 2022 | 37243 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 359 | 0.050 |
Why?
| | Dysbiosis | 1 | 2025 | 180 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 214 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 517 | 0.050 |
Why?
| | Aged | 5 | 2021 | 24172 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2020 | 1949 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2023 | 1569 | 0.050 |
Why?
| | Metabolome | 1 | 2025 | 352 | 0.050 |
Why?
| | Time Factors | 3 | 2018 | 6869 | 0.050 |
Why?
| | Parents | 2 | 2023 | 1423 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2017 | 980 | 0.050 |
Why?
| | Electrochemistry | 1 | 2021 | 76 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | China | 1 | 2021 | 214 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.040 |
Why?
| | Perception | 1 | 2023 | 370 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2021 | 208 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 334 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 106 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 824 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 53 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 144 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 144 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 59 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2021 | 154 | 0.040 |
Why?
| | Mannose | 1 | 2019 | 24 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 110 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 182 | 0.040 |
Why?
| | Linkage Disequilibrium | 2 | 2011 | 258 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 163 | 0.040 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 82 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 223 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 743 | 0.040 |
Why?
| | Butyrates | 1 | 2019 | 60 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 328 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 115 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 543 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 227 | 0.040 |
Why?
| | Fibrinogen | 1 | 2019 | 173 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 649 | 0.040 |
Why?
| | Mothers | 1 | 2005 | 765 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2018 | 187 | 0.040 |
Why?
| | Ascorbic Acid | 1 | 2019 | 179 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 413 | 0.040 |
Why?
| | Sweden | 1 | 2018 | 99 | 0.030 |
Why?
| | Pennsylvania | 1 | 2018 | 131 | 0.030 |
Why?
| | Germany | 1 | 2018 | 128 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 362 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1031 | 0.030 |
Why?
| | Diseases in Twins | 1 | 2018 | 159 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2019 | 349 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 459 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 609 | 0.030 |
Why?
| | Twins | 1 | 2018 | 222 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 433 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 95 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2022 | 825 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 898 | 0.030 |
Why?
| | Capillaries | 1 | 2017 | 114 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1070 | 0.030 |
Why?
| | Automation, Laboratory | 1 | 2015 | 7 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 169 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 310 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2013 | 7685 | 0.030 |
Why?
| | Thyroid Gland | 1 | 2015 | 92 | 0.030 |
Why?
| | North America | 1 | 2015 | 304 | 0.030 |
Why?
| | Fetal Blood | 1 | 2016 | 336 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5530 | 0.030 |
Why?
| | Overweight | 1 | 2018 | 573 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15901 | 0.030 |
Why?
| | Patient Preference | 1 | 2015 | 196 | 0.030 |
Why?
| | Polyneuropathies | 1 | 2013 | 57 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 993 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 516 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1120 | 0.020 |
Why?
| | Genome | 1 | 2014 | 299 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1810 | 0.020 |
Why?
| | Rituximab | 1 | 2013 | 202 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 397 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1072 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 37 | 0.020 |
Why?
| | Exercise | 1 | 2022 | 2086 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 856 | 0.020 |
Why?
| | Genetic Loci | 1 | 2011 | 281 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2010 | 123 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 238 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 2009 | 57 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 695 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 2009 | 64 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2083 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 31 | 0.020 |
Why?
| | Hyperinsulinism | 1 | 2010 | 122 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 47 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 18 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 10921 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 202 | 0.020 |
Why?
| | Telomere | 1 | 2011 | 274 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2009 | 236 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2849 | 0.020 |
Why?
| | Heterozygote | 1 | 2009 | 306 | 0.020 |
Why?
| | Base Sequence | 1 | 2011 | 2176 | 0.020 |
Why?
| | Pedigree | 1 | 2009 | 510 | 0.020 |
Why?
| | DNA | 1 | 2014 | 1441 | 0.020 |
Why?
| | United States | 2 | 2015 | 15074 | 0.020 |
Why?
| | Brain Ischemia | 1 | 2010 | 343 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2925 | 0.020 |
Why?
| | Genome, Human | 1 | 2009 | 418 | 0.020 |
Why?
| | Tissue Donors | 1 | 2010 | 395 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2093 | 0.020 |
Why?
| | Mice | 1 | 2022 | 17828 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2081 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2390 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1746 | 0.010 |
Why?
|
|
Steck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|